Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent ...

At seven-years follow up, invasive disease-free survival was 80.8% with adjuvant T-DM1 and 67.1% with adjuvant trastuzumab alone. Overall survival was 89.1% with T-DM1 and 84.4% with trastuzumab ...

Researchers found no significant differences in safety outcomes between trastuzumab biosimilars and the originator product across subgroups. Trastuzumab biosimilars have similar safety profiles as ...

The FDA has requested additional information regarding vic-trastuzumab duocarmazine to further evaluate the agent for patients with HER2-positive metastatic breast cancer. The FDA has issued a ...

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki improved outcomes compared with capecitabine-based regimens as third-line treatment for certain patients with HER2-positive metastatic breast cancer ...

63.9% reported switching to a trastuzumab biosimilar with Kanjinti being most common (69.8%) 40.8% of patients said they received no prior notification about the switch ...

Trastuzumab deruxtecan (also known as T-DXd and DS-8201) is an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload ...

Among the 261 patients in the trastuzumab deruxtecan group and the 263 in the trastuzumab emtansine group, the median ages were 54 years and most were from Asia (57.1% and 60.8%, respectively ...

Please provide your email address to receive an email when new articles are posted on . As Healio previously reported, the phase 2 DESTINY-Gastric01 trial included 187 patients with HER2 ...

Technology Networks spoke to Mani Krishnan, vice president and general manager, Biopharma and CE, at SCIEX, to learn how a new category of analytical instrumentation – imaged capillary isoelectric ...